• PDF / 169,579 Bytes
• 1 Pages / 595.245 x 841.846 pts (A4) Page_size
• 50 Downloads / 143 Views

DOWNLOAD

REPORT

---

1 S

Carfilzomib/dexamethasone Upper respiratory tract infection with renal involvement, bilateral interstitial pneumonitis and thrombotic microangiopathy: 3 case report

In a study of 69 patients treated with carfilzomib in different treatment schemes between 2013 and 2019 in Spain, 3 patients [ages and sexes not stated], were described who developed upper respiratory tract infection with renal involvement, bilateral interstitial pneumonitis or thrombotic microangiopathy during treatment with carfilzomib and dexamethasone for multiple myeloma [routes and times to reactions onsets not stated; not all dosages and outcomes stated]. The patients with multiple myeloma, started receiving carfilzomib 20 mg/m2 on days 1 and 2 of cycle 1, along with dexamethasone. However, the patients developed treatment related adverse effects, including upper respiratory tract infections with renal involvement (1 patient), bilateral interstitial pneumonitis (1 patient) or thrombotic microangiopathy (1 patient). The patient with bilateral interstitial pneumonitis was admitted to the ICU and the pneumonitis improved upon treatment with unspecified corticosteroids and non-invasive mechanical ventilation. In the patient with thrombotic microangiopathy, resolution was noted following withdrawal of treatment. Gutierrez Lopez de Ocariz X, et al. Descriptive analysis of carfilzomibs toxicity in patients with multiple myeloma. Experience in a Spanish center. Medicina Clinica Practica 803503561 3: No. 6, Nov-Dec 2020. Available from: URL: http://doi.org/10.1016/j.mcpsp.2020.100085 [Spanish; summarised from a translation]

0114-9954/20/1823-0001/$14.95 Adis © 2020 Springer Nature Switzerland AG. All rights reserved

Reactions 26 Sep 2020 No. 1823